Related references
Note: Only part of the references are listed.Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy
Thomas S. Uldrick et al.
SCIENCE TRANSLATIONAL MEDICINE (2022)
Pembrolizumab for previouslytreated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study
John Kuruvilla et al.
LANCET ONCOLOGY (2021)
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma
Kathryn Lurain et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials
Kruti B. Vora et al.
SCIENTIFIC REPORTS (2021)
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Maria Gonzalez-Cao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
The effect of non-AIDS-defining cancers on people living with HIV
Elizabeth Y Chiao et al.
LANCET ONCOLOGY (2021)
Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study
Saeka Egami et al.
FRONTIERS IN ONCOLOGY (2021)
Cancer Clinical Trials in Africa-An Untapped Opportunity: Recommendations From AORTIC 2019 Conference Special Interest Group in Clinical Trials
Abiola Ibraheem et al.
JCO GLOBAL ONCOLOGY (2021)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
The safety and efficacy of immune-checkpoint inhibitor therapy in HIV infected cancer patients.
Phyo Thazin Myint et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection The Phase 2 DURVAST Study
Maria Gonzalez-Cao et al.
JAMA ONCOLOGY (2020)
FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma
Diana Bradford et al.
ONCOLOGIST (2020)
CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies
Blake J. Rust et al.
LANCET HAEMATOLOGY (2020)
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
Kathryn Lurain et al.
CURRENT HIV/AIDS REPORTS (2020)
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib The CheckMate 040 Randomized Clinical Trial
Thomas Yau et al.
JAMA ONCOLOGY (2020)
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
Julius Strauss et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer
Edith Borcoman et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti-PD1/PDL1 Clinical Trials
Joshua E. Reuss et al.
JAMA NETWORK OPEN (2020)
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort
Neil H. Segal et al.
EUROPEAN JOURNAL OF CANCER (2019)
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer A Systematic Review
Michael R. Cook et al.
JAMA ONCOLOGY (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer-A Phase 1 Study
Thomas S. Uldrick et al.
JAMA ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
Oscar Blanch-Lombarte et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
HIV-Associated Cancers and Related Diseases
Robert Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research HIV Working Group
Thomas S. Uldrick et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Cancer care disparities in people with HIV in the United States
Gita Suneja et al.
CURRENT OPINION IN HIV AND AIDS (2017)
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
Adam Diehl et al.
ONCOTARGET (2017)
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al.
BLOOD (2017)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma
Serena Venturelli et al.
BRITISH JOURNAL OF CANCER (2015)
Excess Cancers Among HIV-Infected People in the United States
Hilary A. Robbins et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Excess Cancers Among HIV-Infected People in the United States
Hilary A. Robbins et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy
A. J. Madu et al.
ANNALS OF MEDICAL AND HEALTH SCIENCES RESEARCH (2013)
Share Paper
